In Brief: OncorMed
This article was originally published in The Gray Sheet
OncorMed: Obtains license for BRCA1 genetic markers for breast and ovarian cancer from the Regents of the University of California, Berkeley. In July, the university's application for the genetic markers was allowed by the U.S. Patent Office becoming the first BRCA1 patent to achieve this status, according to OncorMed. The Gaithersburg, Maryland firm currently offers genetic testing services for both BRCA1 and BRCA2 genes for susceptibility to breast and ovarian cancer...
You may also be interested in...
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.